Skip to main content

Drug Interactions between Metvixia and verteporfin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

verteporfin methyl aminolevulinate topical

Applies to: verteporfin and Metvixia (methyl aminolevulinate topical)

Methyl aminolevulinate topical causes your skin to be more sensitive to light in areas where it has been applied. The risk and/or severity of reactions such as redness, scaling, swelling, stinging, and burning may be increased when it is used with other drugs that can also increase sensitivity to light such as verteporfin. You should avoid exposure to sunlight or bright indoor lights (examination lamps, operating room lamps, tanning beds, lights at close proximity) during and for 48 hours after treatment as directed by your doctor. Since sunscreens will not protect you against photosensitivity reactions associated with methyl aminolevulinate topical, you should protect treated areas by wearing a wide-brimmed hat or other protective apparel if exposure to sunlight or other intense lights cannot be avoided. Be advised to reduce your light exposure if you experience sensations of stinging and/or burning. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Photochemotherapeutic agents

Therapeutic duplication

The recommended maximum number of medicines in the 'photochemotherapeutic agents' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'photochemotherapeutic agents' category:

  • Metvixia (methyl aminolevulinate topical)
  • verteporfin

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer